Business Context and Reporting Period
This Form 6-K filing by Alterity Therapeutics Limited, a foreign private issuer, covers the month of June 2019, specifically dated June 4, 2019. The report discloses a corporate governance event regarding the status of the company as a substantial holder of its own securities under Australian Corporations Act regulations.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory notice regarding shareholding status and does not contain financial performance data.
Material Changes
The primary material change reported is the cessation of a voluntary escrow arrangement for the company's own securities.
- Date of Change: June 3, 2019
- Nature of Change: Cessation of voluntary escrow of securities.
- Securities Affected: 269,905,533 fully paid ordinary shares.
- Voting Rights: The release of these shares from escrow affected 269,905,533 votes.
- Consideration: Not applicable.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. The document is strictly a statutory notice of ceasing to be a substantial holder in relation to the specific escrowed shares.
Investor Verification Checklist
- Verify the impact of the 269,905,533 shares leaving voluntary escrow on the company's capital structure and voting dynamics.
- Confirm the terms of the previous escrow agreement to understand the conditions under which the release occurred.
- Review the company's most recent Form 20-F or annual report for actual financial performance metrics, as this 6-K does not contain them.